
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

**Date of Report: December 1, 2016
(Date of earliest event reported)**

Arcadia Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware
**(State or Other Jurisdiction
of Incorporation)**

001-37383
**(Commission
File Number)**

81-0571538
**(I.R.S. Employer
Identification No.)**

202 Cousteau Place, Suite 105
Davis, CA 95618
(Address of principal executive offices, including zip code)

(530) 756-7077
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 1, 2016, Arcadia Biosciences, Inc. (“the Company”) notified Wendy Neal, the Company’s Vice President, Chief Legal Officer and Secretary, that her employment with the Company will terminate effective February 3, 2017. Ms. Neal’s departure is a part of the Company’s efforts to reduce operating expenses by 15-20%, as discussed on November 10, 2016 during the earnings report conference call for the Company’s fiscal quarter ended September 30, 2016. Ms. Neal’s termination is a termination without cause pursuant to Section 3(a) of the Severance and Change in Control Agreement between the Company and Ms. Neal, dated May 11, 2015.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARCADIA BIOSCIENCES, INC.

Date: December 7, 2016

By: /s/ Matthew T. Plavan

Name: Matthew T. Plavan

Title: Chief Financial Officer